Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck’s Bezlotoxumab C. Difficile Data Pave Way For Antibodies

This article was originally published in The Pink Sheet Daily

Executive Summary

Company readies regulatory filings for bezlotoxumab as a monotherapy in preventing C. difficile, following presentation of positive MODIFY I and II data at the ICAAC meeting in San Diego.

You may also be interested in...



Merck Went Own Way On Bezlotoxumab Endpoint And FDA May Not Follow

Merck rejected FDA's recommended endpoint to show efficacy in preventing C. difficile recurrence, which could make it difficult to gain approval for the product, headed to June 9 advisory panel review.

Keeping Track: Telework Kept FDA On Track During Blizzard

The latest drug development news and highlights from our FDA Performance Tracker.

Antibiotics: Officially Encouraged, Increasingly Precise, Still Risky

Anti-infective start-ups getting funded these days say they can boost the odds of clinical success, and reduce the cost of achieving it. Profiles of EnBiotix, Nosopharm, and Spero Therapeutics.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS078932

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel